Novartis Korea draws fire

Novartis Korea’s immorality is under severe criticism from the domestic pharmaceutical industry as the company has recently announced its plan to suspend Glivec’s patient assistance program once generic drugs enter the market.

So far, the company has paid 10 percent of the prescription cost of Glivec for over 4,000 patients. Under the suspended program, patients with chronic myeloid leukaemi...